本研究旨在评价阿扎胞苷（AZA）联合达那唑（DNZ）和沙利度胺（THD）维持治疗对急性髓系白血病（AML）患者强化化疗（IC）后的疗效，回顾性分析了11例患者的临床资料。分析2017年2月至2021年3月于白云医院IC后接受AZA联合DNZ和THD维持治疗的患者11例的临床特征、无复发生存期（RFS）和总生存期（OS）。符合 2016 年世界卫生组织分类的 AML 标准。 11名患者中，女性5例，男性6例，中位年龄45岁（范围23-65岁）。 10 名患者处于第一次完全缓解（CR1），1 名患者处于第二次完全缓解（CR2）。所有患者IC后均接受AZA联合DNZ和THD维持治疗。接受的 AZA 周期中位数为 7 (6-12)。截至2022年6月，中位随访期为37（14-63）个月；一名患者复发，三名患者死亡。 1年和3年的RFS分别为100%和71.1%，3年的OS为100%。AZA联合DNZ和THD维持治疗对于不适合异基因造血干细胞移植的AML患者有效。需要进一步进行大样本和随机研究来验证这些发现。

This study aimed to evaluate the efficacy of azacitidine (AZA) combined with danazol (DNZ) and thalidomide (THD) maintenance therapy after intensive chemotherapy (IC) in patients with acute myeloid leukemia (AML).we retrospectively analyzed the clinical data of 11 patients treated with AZA combined with DNZ and THD as maintenance therapy after IC at the Baiyun Hospital were between February 2017 and March 2021. The patients' clinical features, relapse-free survival (RFS), and overall survival (OS) were analyzed.Eleven cases fulfilled the AML criteria per the 2016 World Health Organization classification. Of the 11 patients, five were females, and six were males, with a median age of 45 years (range, 23-65 years). Ten patients were in the first complete remission (CR1), and one patient was in the second complete remission (CR2). All patients received AZA combined with DNZ and THD maintenance therapy after IC. The median number of AZA cycles received was 7 (6-12). Until June 2022, the median follow-up period was 37 (14-63) months; one patient had a relapse, and three died. RFS at 1 year and 3 years was 100% and 71.1%, respectively, and OS at 3 years was 100%.AZA combined with DNZ and THD maintenance therapy is effective for patients with AML who are ineligible for allogeneic hematopoietic stem cell transplantation. Further studies with large sample sizes and randomized are needed to verify these findings.